Schizophrenia is a debilitating chronic disorder that exacts enormous personal, social, and economic costs. It has traditionally been identified with alterations in the dopaminergic system; however strong preclinical evidence linking schizophrenia with the nociceptin system suggests that this system may play a key role in the etiology of the disease.
Our study utilizes a novel radioligand, [11C]NOP-1A, to image for the first time the nociceptin receptor in participants in vivo. Our group possesses unique expertise and feasibility data to carry out the study.
We are currently seeking participants between the ages of 18 and 40 who meet the following criteria:
• No use of cocaine, opiates, or ecstasy
• No significant head injury
• No metal implants
• Diagnosis of healthy volunteer, or schizophrenia, or clinical high risk for schizophrenia
Overall, our studies take place over 4 sessions:
1. A screening visit (approximately 2 hours)
2. A PET session, where you will complete 2 PET scans (up to 7 hours total, with breaks)
3. A MRI scan (approximately 2 hours)
4. Concluding discharge visit, to provide compensation (approximately 30 to 60 minutes)
You will receive compensation for your participation, transportation costs, and meals. For more information, please contact:
416-535-8501 ext. 30471
dopaminetask.imaging@camhpet.ca